Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates
This article was originally published in Start Up
Executive Summary
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.